<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01548222</url>
  </required_header>
  <id_info>
    <org_study_id>MM2012</org_study_id>
    <nct_id>NCT01548222</nct_id>
  </id_info>
  <brief_title>CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target</brief_title>
  <official_title>CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diabetes Care Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Diabetes Care Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a trial to determine if patients who are well controlled and on basal insulin are&#xD;
      treated with excessive basal dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In many clinical trials, basal insulin is titrated to only a fasting glucose goal. The usual&#xD;
      final dose is &gt;0.4U/kg. In carefully CGM monitored/titrated studies in both basal insulin&#xD;
      alone or in pump-treated T2DM, we have found the basal insulin dose to be &lt;0.3U/kg. This&#xD;
      suggests that if guided by a single daily fasting glucose, titration may result in an&#xD;
      excessive basal dose. This study will examine that issue.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of time CGM glucose is &lt;70mg/dl</measure>
    <time_frame>the subject will be followed for 9 days</time_frame>
    <description>The percentage of time CGM glucose is &lt;70 mg/dl during the basal glucose evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of time CGM glucose is &lt;40 mg/dl</measure>
    <time_frame>the subject will be followed for 9 days</time_frame>
    <description>The percentage of time the CGM glucose is &lt;40 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determined hypoglycaemic episodes</measure>
    <time_frame>the subject will be followed for 9 days</time_frame>
    <description>The percentage of subjects who perceived all CGM determined hypoglycaemic episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight gain</measure>
    <time_frame>the subject will be followed for 9 days</time_frame>
    <description>The mean weight gain since initiating basal insulin fromo retrospectively gathered data.</description>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 2 Diabetes</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from the Diabetes Care Center clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  Age 18 years and above&#xD;
&#xD;
          -  Concurrently on +/-thiazolidnedione +/-DDP IV inhibitors +/-metformin +/- glinides and&#xD;
             basal insulin analogs&#xD;
&#xD;
          -  A1C 10% or below&#xD;
&#xD;
          -  Capable of self monitoring glucose at least 4 x a day&#xD;
&#xD;
          -  Previously compliant with clinical recommendations&#xD;
&#xD;
          -  Fasting blood glucose &lt;110mg/dl average for 3 consecutive days&#xD;
&#xD;
          -  BMI &lt;45 kg/m&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Urinary ketosis&#xD;
&#xD;
          -  Current or expected alternation in insulin sensitivity such as major surgery,&#xD;
             infection, renal failure, glucocorticoid treatment, recent serious hypoglycaemic&#xD;
             episode&#xD;
&#xD;
          -  Currently participating in another clinical trial&#xD;
&#xD;
          -  Using rapid insulin insulin&#xD;
&#xD;
          -  Pregnancy or nursing or the intention of becoming pregnant or not using adequate birth&#xD;
             control&#xD;
&#xD;
          -  Significant liver or heart failure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Diabetes Care Center</name>
      <address>
        <city>Salinas</city>
        <state>California</state>
        <zip>93901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Blonde L, Merilainen M, Karwe V, Raskin P; TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study. Diabetes Obes Metab. 2009 Jun;11(6):623-31. doi: 10.1111/j.1463-1326.2009.01060.x.</citation>
    <PMID>19515182</PMID>
  </reference>
  <reference>
    <citation>Meneghini L, Koenen C, Weng W, Selam JL. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab. 2007 Nov;9(6):902-13.</citation>
    <PMID>17924873</PMID>
  </reference>
  <results_reference>
    <citation>Strange P. Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diabetes Sci Technol. 2007 Jul;1(4):540-8.</citation>
    <PMID>19885117</PMID>
  </results_reference>
  <results_reference>
    <citation>King AB. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study. Diabetes Obes Metab. 2009 Jan;11(1):69-71. doi: 10.1111/j.1463-1326.2008.01014.x.</citation>
    <PMID>19120433</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>February 27, 2012</study_first_submitted>
  <study_first_submitted_qc>March 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>continuous glucose</keyword>
  <keyword>basal insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

